drugset / Trial / NCT01790971

Spinal Morphine for Patients With Obstructive Sleep Apnea

NCT01790971 ↗

Suspended 40 enrolled University Health Network, Toronto
RandomizedParallel-groupTriple-blindTreatment

Summary

Patients with Obstructive Sleep Apnea (OSA) appear to be especially vulnerable to medications that suppress pharyngeal muscle activity such as general anesthetics and opioids. Opioids can depress the ventilator response to airway obstruction and inhibit the awakening response to hypoxia and hypercarbia, resulting in central respiratory depression. OSA is therefore an important risk factor for serious postoperative complications, including perioperative death. While OSA is increasingly recognized as a serious perioperative concern, current clinical practices are highly inconsistent with regard to the management of surgical patients with OSA. Additionally, the relative safety of intrathecal opioids in this patient population remains unknown.

Timeline

Start
2020-01
Primary completion
2020-08
Completion
2020-08

Outcome

Outcome not reported

Stopped: “competing studies”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Morphine Other / unclassified 100 ug Intrathecal